NEW YORK (GenomeWeb News) – Genomatix today announced that it has entered into a cooperative research and development agreement with the Uniformed Service University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine to extend a collaboration aimed at prostate cancer.
The CRADA is for joint research using definitive genetic markers for the differentiation of patients with a favorable versus poor prognosis at the time of diagnosis and primary treatment.
The CRADA extends a collaboration between Genomatix and the Center for Prostate Disease Research (CPDR) at the Uniformed Service University. The alliance will combine translational research services at CPDR with Genomatix's data analysis expertise "in teasing out novel androgen receptor binding sites in the genome and analyzing prostate cancer metastases using prostate cancer model systems and clinical specimens," the German software analysis firm said in a statement.
"Next-generation sequencing opens a new dimension in biomarker research and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring," Thomas Werner, founder of Genomatix, said.
Financial and other terms of the CRADA were not disclosed.